On July 16, innovative drug concept stocks in the A-share market continued to be active. Among them, individual stocks such as Harbin Pharmaceutical Co., Ltd., Hainan Haiyao, and Saili Medical rose more than 14%, Wanbang Pharmaceutical rose more than 13%, and Hongbo Pharmaceutical and Changshan Pharmaceutical followed suit. Behind the activity of individual stocks is the continued rise in popularity across the innovative drug circuit. Currently, at the peak of the disclosure of performance forecasts for the first half of the year. According to the Securities Times and Databao statistics, as of the close of trading on July 16, based on the currently disclosed performance reports and lower net profit limits, there are 20 innovative pharmaceutical companies whose net profit increased year-on-year in the first half of 2026. In terms of future growth expectations, institutional forecasts may provide some reference. According to data treasure statistics, according to the unanimous forecast of 5 or more institutions, there are 22 innovative pharmaceutical companies whose net profit growth rate is expected to exceed 20% in 2026 and 2027. Comparing the latest closing price with the target price predicted by the agency, out of these 22 companies, 13 have room for more than 12% increase in stock prices, including Xinlitai, Yifan Pharmaceutical, Dongcheng Pharmaceutical, Changchun Hi-Tech, and Tiger Pharmaceuticals.

On July 16, innovative drug concept stocks in the A-share market continued to be active. Among them, individual stocks such as Harbin Pharmaceutical Co., Ltd., Hainan Haiyao, and Saili Medical rose more than 14%, Wanbang Pharmaceutical rose more than 13%, and Hongbo Pharmaceutical and Changshan Pharmaceutical followed suit. Behind the activity of individual stocks is the continued rise in popularity across the innovative drug circuit. Currently, at the peak of the disclosure of performance forecasts for the first half of the year. According to the Securities Times and Databao statistics, as of the close of trading on July 16, based on the currently disclosed performance reports and lower net profit limits, there are 20 innovative pharmaceutical companies whose net profit increased year-on-year in the first half of 2026. In terms of future growth expectations, institutional forecasts may provide some reference. According to data treasure statistics, according to the unanimous forecast of 5 or more institutions, there are 22 innovative pharmaceutical companies whose net profit growth rate is expected to exceed 20% in 2026 and 2027. Comparing the latest closing price with the target price predicted by the agency, out of these 22 companies, 13 have room for more than 12% increase in stock prices, including Xinlitai, Yifan Pharmaceutical, Dongcheng Pharmaceutical, Changchun Hi-Tech, and Tiger Pharmaceuticals.